Drug profile · INN
urofollitropin
BRAVELLE
urofollitropin (BRAVELLE) is a follicle stimulating hormone receptor agonist. Route of administration: intramuscular. Current US regulatory status: approved.
Drug details — urofollitropin
- US status
- approved
- Class
- —
- Route
- INTRAMUSCULAR
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
urofollitropin (BRAVELLE) is a follicle stimulating hormone receptor agonist. Route of administration: intramuscular. Current US regulatory status: approved.
Key facts
Mechanism of action
Follicle stimulating hormone receptor agonist
Primary target: Follicle-stimulating hormone receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| NMPA | clinical trials | — |
Related & competitor drugs
Frequently asked questions
What is urofollitropin?
urofollitropin (BRAVELLE) is a follicle stimulating hormone receptor agonist. Route of administration: intramuscular. Current US regulatory status: approved.
What is the brand name for urofollitropin?
BRAVELLE is a marketed brand name for urofollitropin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of urofollitropin?
urofollitropin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.